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‘CORRELATION AND IMPACT OF METABOLIC SYNDROME IN 
BIPOLAR DISORDER’ 
Background: 
  Bipolar Disorder is a chronic episodic illness with frequent alterations of 
mania and depression. Various physical problems are known to affect the course 
and outcome of Bipolar Disorder. Out of them metabolic syndrome is a well-
known co-morbid condition which shares common risk factors and also worsens 
the disease course, may contribute to premature mortality in Bipolar Disorder. 
 Hence, the knowledge about the metabolic abnormalities in Bipolar 
Disorder can help us in planning the treatment of Bipolar Disorder to get better 
prognosis. In this background the present study was conducted in patients with 
Bipolar Disorder to assess the relationship between them. 
Aim:  
To assess the impact and correlation of metabolic syndrome on Bipolar disorder 
patients. 
Objective: 
1. To assess the clinical correlates and socio demographic profile of patients 
with Bipolar disorder. 
2. To assess the various metabolic parameters in Bipolar disorder patients. 
3. To compare the clinical variables of Bipolar disorder in subjects with and 
without metabolic syndrome. 
4. To evaluate the correlation between metabolic parameters and clinical 
variables of Bipolar disorder. 
Methods: 
         A cross sectional study was conducted on patients of Bipolar Disorder 
attending Psychiatric outpatient department of Thanjavur Medical college, 
Thanjavur. Patients who fulfilled ICD-10 criteria for Bipolar Disorder were 
included in the study. All subjects underwent haematological evaluation to 
assess metabolic parameters like, blood glucose, lipid profile and also 
anthropometric parameters. Then they were divided into two groups, with 
and without metabolic syndrome. They were assessed by a semi-structured 
proforma for their socio-demographic status, life chart to assess their course 
of illness. Young Mania Rating Scale (YMRS; for mania) and Hamilton 
Depression Rating Scale (HAM-D; for depression) was administered to 
assess the severity of current episode. 
Inclusion criteria: 
1. All patients of Bipolar disorder (according to ICD-10) attending 
Psychiatric outpatient department of Thanjavur Medical College Hospital, 
Thanjavur. 
2. Age 15 to 60 years. 
Exclusion criteria: 
1. Patients not willing to be a part of the study.   
2. Patients with altered sensorium.     
3. Pregnancy and post-partum (< 6 weeks after delivery or miscarriage). 
 
Results:  
The mean age of the study population was 39 years. More than half of them 
were males, majority of them being from rural areas, educated up to secondary 
level. Half the populations were employed, with women being mainly 
housewives. Majority were Hindus. 
The criteria for the metabolic syndrome were satisfied by 49.18% of patients. 
The prevalence was seen to increase with age, and was higher in the male 
patients. The various components of metabolic syndrome were also found to be 
high. 64% patients were obese, 60.65% were having abdominal obesity, 
hypertension was present in 27.3%, low HDL found in 35.3%, increased 
triglyceride present in 29.5%, and increased fasting blood sugar was present in 
24.59%.  Patients of Bipolar disorder with metabolic syndrome were found to 
have a greater number of lifetime episodes, longer duration of illness, more 
frequent depressive episodes at onset and the life time depressive episodes were 
significantly higher in them. 
 Age of the patient, more number of lifetime depressive episodes and more total 
number of lifetime episodes were found to be associated with the development of 
metabolic syndrome. 
Conclusion: 
  Increasing age, more number of lifetime depressive episodes and 
the more total number of lifetime episodes appear to be predictors for the 
occurrence of metabolic syndrome in patients with Bipolar disorder. We thus 
have valuable insight about the relationship between metabolic syndrome and 
Bipolar disorder. The presence of metabolic syndrome influences the course and 
severity of the illness. It is possible to detect the presence of the metabolic 
syndrome and its components in the early stages of their development and plan 
timely intervention. This would help in altering the course and severity of the 
illness in a favorable manner. 
Key words: 
Bipolar Disorder, Metabolic syndrome, Body Mass Index, Waist 
circumference, Dyslipidemia 
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INTRODUCTION 
Bipolar Disorder is a chronic episodic illness with frequent alterations of 
mania and depression. Episodes of mania and depression are separated by periods of 
recovery and functional ability comparable to their pre-morbid levels. Jules Falret 
provided one of the earliest historical accounts of Bipolar Disorder and called it as 
“La Folie Circulare.”  Later the concept was further redefined when Emil Kraepelin 
segregated it from other psychotic illnesses leading to the separation of “Manic 
Depressive Psychosis” from “Dementia Praecox” 
  Course of Bipolar disorder vary from patient to patient, and it is not fully 
benign, with recent studies suggesting that Bipolar Disorder patients experience 
significant degree of chronicity than previously thought. Various physical problems 
are known to affect the course and also the outcome of Bipolar Disorder. 
Epidemiological studies indicate increased mortality rate in Bipolar disorder patients 
as compared to the general population. One of the major factors conditioning to this 
is the occurrence of obesity, hypertension, dyslipidemia, abnormal glucose levels 
among these patients. Metabolic syndrome, is a combination of metabolic 
abnormalities, is a well-known co-morbid condition which tends to share common 
risk factors with Bipolar disorder and also worsens the disease course, may 
contribute to premature mortality. It is now identified as the risk factor for 
cardiovascular disease and Type 2 Diabetes mellitus. These findings emphasize the 
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need for identification and early intervention of metabolic abnormalities which can 
modulate the severity of the illness to a great extent and reduce the morbidity & 
mortality associated with the illness.  
Most of the present data on Bipolar disorder patients with comorbid 
metabolic syndrome emanates from western studies. India is reported to have higher 
rate of early onset diabetes and hypertension. With this background there is a need 
to explore the relationship between metabolic abnormalities and Bipolar disorder in 
Indian context. The present study is one such attempt. 
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AIM & OBJECTIVE 
Aim:  
To assess the impact and correlation of metabolic syndrome on Bipolar 
disorder patients. 
Objective: 
1. To assess the clinical correlates and socio demographic profile of patients 
with Bipolar disorder. 
2. To assess the various metabolic parameters in Bipolar disorder patients. 
3. To compare the clinical variables of Bipolar disorder in subjects with and 
without metabolic syndrome. 
4. To evaluate the correlation between metabolic parameters and clinical 
variables of Bipolar disorder. 
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HYPOTHESIS 
      The clinical and socio demographic profile of Bipolar disorder patients with 
metabolic syndrome is different from those without metabolic syndrome. 
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REVIEW OF LITERATURE 
 
PREVALENCE OF METABOLIC ABNORMALITIES: 
The burden due to Bipolar disorder (BPD) is mainly related to psychiatric 
symptoms and dysfunction related to the disease; other medical co-morbidities 
are also common in this Bipolar disorder (1). There is a higher prevalence of 
metabolic abnormalities in BPD patients when comparing to the general 
population (2, 3 and 4). BPD patients found to have a wide array of metabolic 
abnormalities like weight gain, hypertension, dyslipidemia, diabetes mellitus 
and abnormal thyroid functions which has impact in its course and outcome in 
an adverse manner (5, 6). 
OBESITY IN BIPOLAR DISORDER 
The prevalence of obesity was found to be consistently high in 
association with Bipolar disorder (6, 7 and 8). The objective measurement of 
obesity being done by measuring waist: hip ratio and body mass index (BMI). 
BMI is a quantitative measurement of obesity (estimated by body weight in 
kilogram / height in meters square). While the waist: hip ratio is the assessment 
of the type of body fat distribution. Based on the BMI, WHO classified obesity 
(9) as BMI greater than 30 and BMI more than 40 considered as morbid obesity.  
It is important to note that of late WHO has modified obesity criteria for 
Asians (10), obesity could be defined as BMI above 25 and over weight when 
BMI is more than 23. Central obesity is defined as waist circumference >80cm 
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for women and waist circumference >90cm in men by the same WHO criteria 
(10). This was probably in light of a study done by WHO which found that 
urban Asians with a BMI between 23-24 have an equivalent risk of 
hypertension, diabetes mellitus, and dyslipidemia as a BMI in the range of 25-
29.9 in white population (10 and 11).  
Individuals with Bipolar disorder are at a risk for obesity due to multiple 
factors like sedentary life style, eating habits and medications (5). Over-weight, 
obesity and extreme obesity are common in people with Bipolar disorder (12). 
Elmslie et al (7) studied eighty nine euthymic Bipolar outpatients with sex 
matched control subjects and found that female subjects were more often obese 
( 20% vs 13% ) and overweight (44% vs 25%) when comparing to their female 
controls. Male subjects were more often found to be obese (19% vs 10%) than 
their male controls. Distribution of the excess fat in the Bipolar patients was 
more at central, with fifty nine percent of female patients compared to seventeen 
percent of female controls; they had waist: hip ratio >0.8 (statistically 
significant) and 58% of male patient compared to 35 % of male controls having 
waist: hip ratio >0.9 (statistically significant)7.  
Pharmacotherapy showed impact on body weight; study on 50 patients 
showed increase in body weight in 32% of patients on comparing with only 
19.8% in controls (13). A Danish study (14) reported that weight gain was 
associated with female gender, weight at diagnosis, and antidepressant use but  
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not with thyroid concentration or lithium or antipsychotic use. Likewise 
another study found that weight gain was associated with antipsychotic use but 
not with lithium use (7). 
Most important factor related to increase in obesity related diseases is 
weight gain and another factor is excessive centrally deposited adipose tissue. 
Prediction of coronary heart disease is significantly associated with distribution 
of body fat rather than total body fat (15 and 16). 
 
HYPERTENSION IN BIPOLAR DISORDER:  
There are reports stating that Bipolar disorder patients are found to have 
high blood pressure; they also have elevated risk for death due to cardiovascular 
diseases (17-19). The systolic blood pressure was higher during manic episode 
when compared to the baseline (17). The underling pathophysiological process 
for the high blood pressure is proposed to be the abnormal regulation of the 
sympathetic nervous system. One of the recent studies found out an interesting 
finding that the resting heart rate did not differ in euthymic Bipolar patients. 
However, people with Bipolar disorder did have significant lower heart rate 
variability (20). Excessive regularity in heart rate may reflect a level of cortisol 
control that has been reset to withstand stressful changes in relation to mood 
stability. This may dampen changes associated with fluctuation of mood and 
also may contributes to cardiac fluctuations (20).
 
There are some studies which 
studied uptake of glucose by the central nervous system which is done by 
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insulin in response to the oral intake of glucose; they found that there is 
significant overlap between this mechanism and the sympathetic overactivity; 
they suspect this mechanism to be an etiopathogenesis of hypertension in BPD 
patients (21). Sympathetic activity was also found to be high in obesity (22). 
Some studies link increased hypothalamo-pituitary axis activation to the 
increased sympathetic activity; they also say that, this has better correlation than 
the insulin related mechanism (23); so they suggest both hypothalamo-pituitary 
axis activation and sympathetic over activity go hand-in-hand.
 
 
DYSLIPIDEMIA IN BIPOLAR DISORDER 
Dyslipidemia is common among patients with Bipolar disorder. About 
two-third of Bipolar patients were found to have borderline dyslipidemia and a 
quarter met the criteria of high risk dyslipidemia. Grover et al (24); in this 
review of 19 studies reported prevalence of abnormal serum level of HDL 
ranging from 21.7 – 71 and triglyceride level from 22.7 -58.8 among patients of 
Bipolar disorder. Lipid profile of Bipolar disorder patients is influenced by 
many other confounding factors like overweight, diabetes mellitus and 
medications (25). Serum lipid level probably has a clinical correlation, 
manifested as violence and suicidal behaviour in Bipolar patients (25). Simon J. 
Evan et al (26) reported a positive correlation between personality factors and 
violent reaction with low plasma lipid levels in the patients of Bipolar disorder. 
Engelberg (27) proposed as the cholesterol is an important ingredient of the 
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neuronal cell membrane, which plays an important role in the transport of 
neurotransmitters hence modulating its effects. Lower cholesterol levels found 
to be associated with central serotonergic dysfunction and results in aggressive 
and impulsive behaviour (28). 
 
DIABETES MELLITUS IN BIPOLAR DISORDER 
High rates of insulin resistance and impaired glucose tolerance in 
individuals with psychiatric illnesses were recognized even before the 
introduction of neuroleptics (29 and 30). Comparing with general population 
BPD patients were more commonly found to have impaired glucose tolerance 
and insulin resistance is found to be more common in individuals with Bipolar 
disorder than in the general population (31). Studies have established depression 
as an independent risk factor for diabetes (32) and this link has been explored in 
Bipolar patients as well. When comparing with general population Bipolar 
patients who were hospitalized have significantly high prevalence (three fold 
high; i.e. 9.9% Vs 3.4%) of diabetes mellitus (33; Cassidy et al). Diabetes 
mellitus is more prevalent in schizophrenia and so schizophrenia is taken as 
an independent risk factor for diabetes mellitus; some studies revealed that it 
is also equally prevalent in Bipolar patients as in schizophrenia (34) while 
other studies have found the rates of diabetes mellitus was actually higher in 
Bipolar patients (26% Vs 13% ; p<0.006) (35). 
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Theories link a tyrosine hydroxylase / insulin /  insulin-like growth factor 
II(TH/INS/IGF-II) gene cluster on the short arm of chromosome 11 as a 
susceptibility locus for diabetes mellitus (36, 37) and link tyrosine hydroxylase 
marker to an association with Bipolar disorder (38, 39). Patients with Bipolar 
disorder with diabetes mellitus are reported to experience more severe and 
chronic course, with greater numbers of episodes, with significantly more rapid 
cycles (40) and longer duration of hospitalization than non-diabetic patients 
(33). 
 
THYROID ABNORMALITIES IN BIPOLAR DISORDER: 
Thyroid hormone is related to wide variety of bodily functions. Hence 
thyroid dysfunction leads to variations in various metabolic parameters. Thyroid 
abnormality may present as hyperthyroidism and hypothyroidism and the later 
may be subclinical or overt. Thyroid abnormalities are studied in Bipolar 
patients. Hypothyroidism in BPD patients is linked to more likelihood of 
depressive episodes; hyperthyroidism leads to more manic or euphoric episodes 
(41). These thyroid abnormalities are also leads to increased cardiovascular 
related mortality and morbidity (42-45).  
Thyroid dysfunction in BPD patients has significant role in its prognosis. 
These patients show poor response to pharmacotherapy than those with normal 
thyroid function (46). 
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Thyroid abnormality in BPD patients is also linked to Lithium therapy 
(47). Lithium is known to inhibit the release of thyroid hormone and so results 
in hypothyroidism with elevated TSH levels. There are studies available on role 
of thyroid supplement to patients on lithium (47).  
 
FORMULATION OF METABOLIC SYNDROME: 
The metabolic syndrome is a mixture of parameters which makes the 
patients more vulnerable to cardiovascular and diabetes related morbidity and 
mortality. The basic pathology is central obesity and insensitivity to insulin. 
There are some other pathologic factors for this syndrome; they include 
physical inactivity, non-alcoholic steato-hepatitis, polycystic ovarian disease 
and hereditary lipodystrophies. 
There are few diagnostic criteria available for this syndrome. One of 
them is WHO criteria. It states that: 
1. Abnormal waist-hip ratio. 
2. Decreased HDL level. 
3. Elevated triglyceride level. 
4. High fasting glucose level. 
5. Hypertension. 
If three of the five had been there, then the patient is said to have metabolic 
syndrome according to WHO criteria. 
Another one, the Third Report of the US National Cholesterol Education 
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Program, Expert Panel on Detection, Education, and Treatment of High Blood 
Cholesterol in adult is the most often cited definition. Most criteria require three 
parameters to be abnormal to be called as metabolic syndrome. 
Another criterion called International Diabetes Federation (IDF) and National 
Cholesterol Education Program Adult Treatment Panel-III is available. 
According to IDF waist circumference abnormality is an essential criterion; 
and needs other two criteria to be called as metabolic syndrome. 
There are steps being taken to make the criteria uniform. 
 
ASSOCIATION BETWEEN METABOLIC SYNDROME AND BIPOLAR 
DISORDER: 
There is overlap between symptoms of Bipolar disorder and metabolic 
syndrome (57). Comparing with the general population prevalence of metabolic 
syndrome is significantly plenty in Bipolar disorder patients. The prevalence 
was even higher in hospitalized Bipolar patients as compared to the community 
sample (56% Vs 25%). A meta-analysis of 37 studies (58) reported that the 
prevalence of metabolic syndrome was around 37.1 % in the Bipolar disorder 
patient. Further Grover et al (24) reported that the prevalence of metabolic 
syndrome range from 16.7 to 67 in his review of 34 studies. In the same review 
Grover et al (24) pointed that waist circumference (WC) and raised blood 
pressure (BP) were the most common abnormal parameters reported across 19 
studies. Raised waist circumference was seen in 30-85% of Bipolar patients, 
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while 6-62% were found to have a raised blood pressure or were already on 
antihypertensive medication. Elevated fasting blood glucose or patients on oral 
hypoglycemic medication were the least commonly reported (6-43.5%), Low 
level of high density lipoprotein (HDL) were seen in 21.7-67.6%, and high 
triglyceride level in 22.7-58.8%. Lipid abnormalities were of intermediate 
prevalence (24). Fagiolini et al (6) enumerated these metabolic abnormalities in 
a group of 171 patients of Bipolar disorder and reported 74% of these patients 
were obese particularly the abdominal type of obesity was most common (49%) 
in addition to that 41% were hyperglycemic , 48% were with elevated 
triglycerides or were receiving cholesterol- lowering medication, 23% were 
having low levels of HDL cholesterol, 39% were hypertensive and 8% had high 
fasting glucose or were on anti-diabetic medication use (6). 
Differing findings in these studies may be due to difference in sample 
size and also the different diagnostic criteria used for Bipolar disorder and 
metabolic syndrome; variation in sample composition method and the 
difference in method of taking anthropometrics and metabolic parameters (58). 
Striking geographical variation also noted in the prevalence of metabolic 
syndrome in patients with Bipolar disorder (58). Prevalence of metabolic 
syndrome was highest in New Zealand and Australia (64.2%) followed by 
South America (38.2%) and Europe (32.4%), further prevalence was higher in 
North America (49.3%), prevalence in Asian countries was 39.6%. 
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DETERMINANTS OF METABOLIC SYNDROME: 
Metabolic syndrome and Bipolar disorder have overlapping physical 
factors like obesity. They also share abnormalities in metabolism of glucose and 
insulin, and hormonal and neuronal abnormalities like the hypothalamic-
pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid (HPT) axis (34).  
Along with these overlapping physical factors, drugs used for the 
treatment of Bipolar disorder also increases the symptoms of Bipolar disorder; 
they are known to cause increase in weight, metabolic abnormalities, 
disturbances in lipid and glucose metabolism, which predispose to diabetes 
mellitus, and other metabolic abnormalities (59). 
Factors predispose to the metabolic syndrome in the patients of Bipolar 
disorder can be summarized under following main headings:- 
1. Genetic 
2. Endocrine 
3. Lifestyle and behavioural risk factors 
4. Pharmacotherapy induced metabolic syndrome  
 
1. GENETIC FACTORS:- 
Advancement in medical technology identified the association of genetics 
of Bipolar disorder and the metabolic syndrome. They found that seven different 
diseases (including Bipolar disorder) have a common biological pathway (60). 
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 Further analysis of this sharing of genetic basis leads to identification of 
strong correlation of genetics between the following three conditions (60). 
 Bipolar disorder. 
 Coronary artery disease. 
 Type-2 diabetes mellitus.  
 
2. ENDOCRINE:- 
Correlation of Bipolar disorder and metabolic syndrome could be 
attributed to sharing of common systems like HPA axis (41), the immune 
system (61 and 62), autonomic nervous system, glucose and insulin regulation, 
and regulation of homeostasis (63). There are studies highlighting the higher 
prevalence of hypothalamo-pituitary axis abnormalities of in Bipolar disorder 
patients than in general population (41).
 
Presence of stress, both in manic and 
depressive episodes, elevates the serum cortisol (64). Evidence also suggests that 
psychological stressors may predate the onset of Bipolar disorder (65 and 66) 
and also the relapse (67).  The most important neuroendocrine pathology in 
major depression is overactivity of the hypothalamic-pituitary-adrenal (HPA) 
axis which is considered the central control of the stress response (68).
 
Various neuroendocrine abnormalities had been demonstrated in Bipolar 
disorder patients. Few of them are the followings: 
1. Disturbances in normal diurnal variation in cortisol level.  
2. Increased basal cortisol level. 
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3. Loss of normal suppression of cortisol level by dexamethasone. 
4. Disturbed response of HPA axis to various stressors. 
Abnormalities in cortisol are not confined to the depressive phase, with 
abnormal dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test 
results being found in people with mania as well (74). Medication used in either 
phase may have an impact on the cortisol response. The abnormalities of HPA 
axis may be normalized in following treatment of depressive symptoms (75, 
76); but one study showed different result with no such normalization (77).
 
 
Regarding treatment of resistant unipolar depression Lithium 
augmentation increased the cortisol response to dexamethasone suppression test 
(78); although another recent study of people with Bipolar disorder did not show 
this increase (72). A treatment study of people with schizophrenia found that 
typical neuroleptic drugs suppress blood cortisol levels and decreased the 
number of patients who are dexamethasone non suppressors (79). 
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS:- 
Various derangements in hypothalamic-pituitary-adrenal axis are seen, 
this leads to persistent elevation of the cortisol. Elevated cortisol makes the 
following cascades. 
 Blunts the insulin mediated uptake of glucose by the cells; it leads 
to elevated blood glucose level; the elevated glucose is converted  
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into fat and gets deposited in coronary arteries to produce coronary 
artery disease. 
 Impaired leptin signalling: this brings the obesity. 
 Persistently elevated cortisol also promotes deposition of fat in 
viscera. 
 Action on lipoprotein lipase: Promotes influx of fat into adipose 
tissues. As more fat is deposited in the viscera, triglycerides are 
getting attracted more and get accumulated. 
 Promotion of insulin resistance. 
 
 
IMMUNE FUNCTION:- 
There are known linkage between the Bipolar disorder and the immune 
pathways. Both mood disorders produce abnormality in immunity and immune 
derangements produce mood disorders. Later was demonstrated in few studies 
and they showed various mood disturbances like, altered sleep, anorexia and 
anhedonia can be produced by administration of various inflammatory 
mediators. These exposures to inflammatory mediators are known to cause 
depression (88 and 89). 
Conversely immune response is also altered in mood disorders. 
Overexpression of various immune mediators had been demonstrated in mood 
disorders, especially in depression (61 and 62). These studies suggested the 
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linkage between the mood disorders and overexpression of pathways of immune 
process. More than this they also demonstrated that this overexpression comes 
to normal after psychotherapy for the depression (87).  
Several immune mediators have been linked to Bipolar disorder. Out of 
this interleukin-6, C-reactive protein and interferon- γ are playing the major 
role. Level of these mediators also shows correlation with cardiac related 
morbidity and mortality. 
Interleukin-6: Interleukin-6 level is increased in depression; this is mediated by 
leptin. This results in increased adipocyte deposition and thereby obesity. It 
results in increased obesity related morbidity and mortality. Another important 
effect of elevated interleukin-6 is its effect on corticotrophin releasing hormone. 
Interleukin-6 is a strong stimulator for production of corticotrophin releasing 
hormone. It leads to increased hypothalamo-pituitary axis activation and thereby 
results in increased cortisol level in blood (95). This blunts the cellular and 
humeral immune response. So the final picture is elevated immune mediators 
but with blunted immune response (96).  
C-reactive protein: C-reactive protein is also elevated in depression. It is 
secreted by liver. It shows strong correlation with cardiac related morbidity and 
mortality. 
Interferon-γ: This is shown to be related to Bipolar disorder recently. It causes 
cascade of events as below (97). 
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 Another effect of the above cascade is effects of 3-hydroxy- kynurenine and 
quinoline, which are metabolites of the above sequence causing damage to brain 
parenchyma (97 and 98). 
More than these elevated inflammatory mediators are also linked to the 
following diseases: 
1. Osteoporosis. 
2. Cancer. 
3. Inflammatory arthritis. 
4. Alzheimer’s disease. 
 
3. LIFE STYLE AND BEHAVIOUR: 
Behavioural patterns and life style are also known to have significant 
role in the co-incidence of the metabolic syndrome and Bipolar disorder. Lack 
of exercise (57, 102-104), poor eating habit
 
(105), and especially substance use 
20 
 
 
are the important contributors (106).  
Substance abuse disorders had been demonstrated to have higher 
incidence in Bipolar disorder patients than in general population. In general 
population the incidence was 12.8%; but in Bipolar disorder it is shown to be 
significantly higher at 35.3% (108) (NESARC; study on 43093 respondents). 
They also demonstrated the 12-month prevalence of substance use disorders, 
which was about 27.9% in mania patients and 26.6% in hypomania; but the same 
was only 9.4% in the general population (108).   
In another study (109) on Bipolar disorder patients nicotine dependency 
was significantly higher at 70%; and use / abuse of alcohol was also greater than 
the general population. In another study the alcohol use in Bipolar disorder patients 
was reported to be 21.4 to 54.5% (110).   
Other life style factors associated with development of obesity and 
metabolic syndrome in Bipolar disorder patients are lack of physical activity and 
overeating (57, 102-104).  
There are multiple known factors which cause obesity and metabolic 
abnormality. They can be listed as following: 
1. Increased calorie intake. 
2. High refined sugar intake. 
3. Increased proportion of energy intake from carbohydrate. 
4. Higher intake of sugar containing drinks. 
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All these factors are found to be high in case of patients of Bipolar disorder on 
a study by Elmslie et al (105).  
Apart from all these factors basal metabolic rate is also found to be low in 
Bipolar disorder patients than normal controls (111) (Soreca et al). 
Pattern of eating is also found to be abnormal in Bipolar disorder patients. 
They are controlled by dopamine mediated reward- like systems and their 
abnormality shows significant association with Bipolar disorder (112, 113 and 
114).  
In patients with decreased dopamine level in these reward pathways, it 
has been called as ‘reward deficiency syndrome’. In this setting there are many 
compensatory mechanisms which cause increased intake of food by reinforcing 
behaviours (114, 115).  
There are strong evidences for strong association, in female patients of 
seasonal affective disorder, between a gene variant called, the 7-repeat allele of 
the dopamine-4 receptors gene, which decreases affinity for dopamine, and 
binge-eating behaviour (116). 
Binge eating is also a common associated morbidity in Bipolar disorder 
patients. In a study by Ramacciotti et al (117), they demonstrated that 27.5% of 
patients with Bipolar disorder encountered diagnosis of binge eating disorder 
/ bulimia nervosa, either as a current diagnosis or in their life time. Kruger et 
al also showed similar results (118). 
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Health care seeking behaviour also is deranged in Bipolar disorder 
patients when comparing with normal population. So many of the illnesses in 
these patients are underdiagnosed or go unnoticed in these patients (119). 
Cradock-O’Leary et al (120) also founded similar results in Veterans Affairs (VA). 
 
4. PHARMACOTHERAPY:- 
Both typical and atypical antipsychotics are available in treatment of 
Bipolar disorder. Because of extra-pyramidal side effects typical antipsychotics 
had been widely replaced by the second-generation antipsychotics (121, 122).  
There are studies available stating that metabolic syndrome related adverse 
effects are more common with atypical antipsychotics when comparing with mood 
stabilizers (6, 123 and 124). Various other adverse effects related to metabolic 
syndrome had been demonstrated with second generation antipsychotics. They 
show more weight gain and abnormalities in carbohydrate and fat metabolism 
(125). Out of atypical antipsychotics clozapine and olanzapine are known to have 
higher incidence of metabolic syndrome related adverse effects and weight gain; 
they show higher incidence of diabetes mellitus and hyperlipidaemia (121); 
risperidone and quetiapine show little lesser incidence of these effects than the 
previously mentioned drugs (121).  
Mechanism of action for the adverse effect of these drugs had been 
studied. Histamine receptor mediated action of clozapine caused over activity of 
the adenosine phosphate – protein kinase. This enzyme is related to appetite, 
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overexpression of which causes increased appetite and over intake of food 
(126).  
On the other case metabolic syndrome related adverse effects are not 
significantly encountered or not at all in aripiprazole and ziprasidone (121), but 
needs further studies. 
Mood stabilizers are also shown to produce weight gain. Several studies 
demonstrated the occurrence of weight gain with these drugs. Monotherapy with 
lithium showed 13% incidence of significant weight gain after one year; this 
was around 21% for Divalproex; comparing with placebo it was seen only in 
seven percent of subjects (127) (Bowden et al).  
Lithium was shown to have effect on carbohydrate metabolism. Action of 
lithium on carbohydrate was similar to insulin, with augmentation of glucose 
absorption in gastrointestinal tract and increases appetite (128, 129). On the 
other hand valproate influences fat metabolism (130).  
Thirst is also increased by these drugs (131); this may result in high 
intake of sugar containing high calorie drinks which results in weight gain. 
Furthermore appetite is also increased by these drinks. Action on hypothalamus 
is said to be the cause of increase in thirst.  
Other mood stabilizing drugs did not show significant weight gain. 
Monotherapy with lamotrigine for Bipolar disorder did not showed 
significant weight gain in study by Sachs et al (132). Similar to their study  
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Ketter et al did with carbamazepine; they also reported no weight gain after six 
months (133).  
Regarding antidepressants mechanism of action for adverse effects differs 
for each class of antidepressants. Tricyclic antidepressants, which are 
adrenergic, so they blunt response to insulin and causes hyperglycaemia. 
Whereas drugs acting via serotonin, i.e. SSRI have different action; they show 
favourable actions on carbohydrate metabolism, causing glycaemia control 
(134). So that weight gain is more common with tricyclic antidepressants than 
SSRIs. Mirtazapine is an exception, as the mechanism of action is between 
tricyclic agents and SSRI, they show higher incidence of weight gain than 
others (135). 
 
IMPACT OF METABOLIC SYNDROME ON BIPOLAR DISORDER 
Bipolar disorder is one of the leading causes of worldwide morbidity and 
premature mortality, according to WHO it is in the top ten (136). It also has been 
suggested that it causes more economic burden than other behavioural health 
conditions (137). It causes more illness burden and more need and use of health 
services which directly increases economic burden. It also causes interferences 
in work flow function (137 and 138).  
It not only shows its own individual risks, but it also adds additional co-
morbid conditions which adds risks further (139); it is seen that there is six fold 
increase in diabetes mellitus (140). Whereas risk for coronary artery disease 
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related mortality is increased by three to six times (139, 141 and 142).  
Most common cause of mortality in Bipolar disorder patients is 
cardiovascular disease related death. Another cause of death in these patients 
was endocrine related complications. There was three times increase in this 
complication in these patients comparing with general population (19).  
There are other diseases associated with Bipolar disorder, as listed earlier 
they include, fatty infiltration of liver, polycystic ovarian disease, gall stones & 
lipid derangements. Apart from all these diseases they also show increased 
tendency to commit suicide. As a whole the life expectancy has been reduced 
(138). 
Grover et al (24) in his review of 34 studies pointed some clinical 
correlates of metabolic syndrome Bipolar disorder patients. These are longer 
duration of illness,
144,145 
greater numbers of life time depressive and manic 
episodes with more intense and treatment resistant index affective episodes 
(146), depressive onset (147); index manic episodes were less severe (148); age 
of onset at index episode was delayed; first treatment for both phases are delayed 
(149). The use of different criteria of metabolic syndrome and the effect of 
ethnic and geographical factors play a significant role in the pattern and 
prevalence of metabolic syndrome.  
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In this aspect most of the information is contributed by western studies 
and Indian data is sparse. Moreover the studies do not investigate the 
relationship between types of index episode, total number of lifetime episodes, 
and severity of the current illness with the prevalence on metabolic syndrome. 
The present study attempts to explore these associations. On the back ground of 
high prevalence of early onset diabetes and hypertension in the Indian 
population there is a need for examination of the relationship between metabolic 
syndrome and Bipolar disorder and hence the requirement for the present study. 
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MATERIALS AND METHODS: 
Study setting:  
The present study was conducted on patients attending Psychiatric 
outpatient department of Thanjavur medical college hospital, Thanjavur, Tamil 
Nadu. 
Study period:  
From January 2015 to June 2015. 
Study design:  
A Cross sectional study. 
Sample size:  
61 Patients who fulfilled ICD-10 criteria for Bipolar disorder have been 
included in the study. 
Inclusion criteria: 
1. All patients of Bipolar disorder (according to ICD-10) attending 
Psychiatric outpatient department of Thanjavur Medical College 
Hospital, Thanjavur. 
2. Age 15 to 60 years. 
Exclusion criteria: 
1. Patients not willing to be a part of the study.   
2. Patients with altered sensorium.     
3. Pregnancy and post-partum (< 6 weeks after delivery or miscarriage). 
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METHODS OF DATA COLLECTION 
The study protocol was presented to the Ethical Review committee of 
Thanjavur Medical College and got approved. The study was conducted at the 
Department of Psychiatry of Thanjavur Medical College in Thanjavur. Male and 
female patients with age more than 15 years with diagnosis of Bipolar disorder 
(according to ICD-10), were included in the study. Prior to recruitment into the 
study a written informed consent was obtained from all the patients.  
 Socio-demographic characteristics and clinical details of all the 
subjects were recorded using a semi-structured pro forma. 
 Sample was selected by purposive sampling and allocated to the 
inclusion or exclusion group. 
 61 patients with a diagnosis of Bipolar disorder were assessed over a 6 
months period (From January 2015 to June 2015). 
 Psychiatric diagnosis was made by using the criteria according to 
International Classification of Diseases - Tenth version (ICD-10). 
 
 
ASSESSMENT: 
 A detailed assessment of anthropometric parameters like height (cm), 
body weight (kg) and body mass index (BMI), waist circumference (cm) 
was made. 
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 Fasting venous blood sample was collected with aseptic precautions and 
sent to laboratory for the examination for blood glucose, serum lipid, and 
thyroid profile. 
 The severity of symptoms of present depressive episode was assessed by 
using Hamilton Depression Rating Scale (HDRS). 
 The severity of symptoms of present manic episode was assessed by using 
Young Mania Rating Scale (YMRS). 
 Metabolic syndrome was ascertained by using a consensus definition56 
according to which three or more criteria are required to be satisfied. The 
criteria are high blood pressure (≥130/85), high triglycerides level (>150 
mg/dl), low level of HDL (<40 mg/dl for male and <50 mg/dl for female), 
impaired fasting sugar (≥100 mg/dl), and high waist circumference (>90 
cm for males and >80 cm for females). 
PHYSICAL EXAMINATION AND ANTHROPOMETRIC 
MEASUREMENTS: 
General physical examination was done including pulse and blood 
pressure measurement according to the prescribed methods 
 
EXAMINATION OF PULSE 
Pulse is peripheral extension of the heartbeat. To measure the pulse at the 
wrist of participants, examiner’s index and middle fingers of right hand were 
used to locate the pulse on the wrist at the base of the thumb. Using a watch 
with a second hand, pulse was counted for 1 minute to get the pulse rate. 
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MEASUREMENT OF BLOOD PRESSURE: 
Blood pressure is measured using standard mercury manometers in supine 
position. The cuff was wrapped around upper arm at about the level of heart and 
inflated till the pressure sufficient to obliterate the vessel; then the cuff was 
deflated slowly. A stethoscope was placed over brachial artery region to listen 
for Korotkoff sound. With gradual deflation of the cuff, the point of appearance 
of clear tapping sound in time with the heart beats was taken as the systolic 
blood pressure. As the cuff deflated further, the sound would become quieter; 
before disappearance it gets louder. The point at which the sound disappeared 
was taken as the diastolic blood pressure. In cases of elevated pressure above 
≥130/85, two readings were taken at 5-minute intervals; a third measurement 
also may be taken in the setting of only one measurement is elevated in the 
initial two measurements. The third reading was taken after 30 minutes; the 
lowest of these reading was included for analysis. 
 MEASUREMENT OF BODY WEIGHT: 
To measure the weight, individual was first asked to remove their shoes, 
and heavy garments, and empty their pockets of heavy articles that could affect 
the correct recording of weight. Next, they were asked to stand on a weighing 
scale placed on a hard-floor with reading set at zero with weight distributed 
evenly to both feet. He/she was then, asked to look straight and the weight was 
recorded on the scale in kilograms. 
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MEASUREMENT OF HEIGHT: 
To measure the height, individuals were asked to remove their shoes. 
Then he/she was asked to stand with his/her back to the height rule. The 
back of the head, back, buttocks, calves and heel would be touching the wall 
with feet placed together. They were then asked to look straight so that the 
top of the external auditory meatus (ear canal) was at level with the inferior 
margin of the bony orbit. The head piece of the stadiometer or the sliding 
part of the measuring rod was lowered so that the hair (if present) is 
pressed flat. The height was then recorded to the nearest centimetre unit 
shown on the scale. 
 
MEASUREMENT OF WAIST CIRCUMFERENCE: 
To measure the waist circumference of the subjects, individual was 
asked to remove tight clothing, including the belt and be without heavy 
outer garments. He/she was made to stand with their feet fairly close 
together and their weight equally distributed to each leg. Participants were 
asked to breathe normally; the reading of the measurement was taken at 
the end of gentle exhalation. Waist circumference was measured at a level 
midway between the inferior costal margin and superior iliac crest, at the 
end of normal expiration while standing, with the help of a tape all around 
the body in horizontal position, measurement recorded at the point of 
resolution of the tape. 
32 
 
 
 
CALCULATIONS OF BODY MASS INDEX (BMI): 
 
The body mass index (BMI) or “Quetelet index” is a measurement of 
human body fat; it is based on two parameters; one is individual’s weight and 
another is vertical height.  
Body mass index (BMI) is calculated by dividing the subject’s body 
weight in kilograms by the height in meter square. 
 
Formula: -    BMI = weight (Kg) / Height (m)2. 
 
BLOOD INVESTIGATION & METABOLIC PARAMETERS: 
Under aseptic precaution fasting venous blood sample was collected; 
estimation of fasting blood sugar (FBS), post prandial blood sugar (PPBS), 
thyroid profile, and lipid profile were done. 
 
DESCRIPTION OF TOOLS USED 
SEMI-STRUCTURED PROFORMA 
A semi structured proforma was applied to document socio-demographic 
and clinical details. For the documentation of course of the Bipolar disorder in 
the patient life chart method was used and the severity of the episode was 
assessed by using appropriate scales. 
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HAMILTON DEPRESSION RATING SCALE-21 (HDRS) 150-152 
Rating scale for depression developed by M Hamilton is called as the 
HDRD (also known as Ham-D); it is the most commonly scale for depression 
assessment. Seventeen items are there in the original version. It has been 
proved that it is not only useful in the initial assessment, but also in the 
treatment follow up. Clinician interviews the patients and asks for particular 
symptoms; e.g., depressed mood, guilty feelings, suicide thought, and 
disturbance in sleep, level of anxiety and loss of weight. It takes around 
fifteen minutes to complete the interview and scoring. The clinician puts 
score for each symptom which is constructed that ranges from 0 (not 
present) to 4 (extreme symptoms). 
 
YOUNG MANIA RATING SCALE (YMRS) 153, 154 
The Young Mania Rating Scale (YMRS) is also a most commonly used 
rating scales, but for assessment of manic symptoms. It has been designed with 
eleven items; it is a subjective report based on based on the patients, fregarding 
their clinical condition over the previous 48 hours. Other informations are taken 
during the interview based on clinical observations. Published descriptions are 
available for selecting items. 
It follows the Hamilton Rating Scale for Depression (HAM-D) style, with 
each item given a severity rating. Irritability, speech, thought content, and 
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disruptive/aggressive behaviour are the four items that are graded on a 0 to 8 
scale; rest seven items are graded on a 0 to 4 scale. Weightage for individual 
items also differs; these above mentioned four items are given two fold weights 
of the others; the basis is to compensate poor cooperation in severely ill 
patients. Different anchor points are available for each severity grade.  
There are lot of variations in the baseline sore of YMRS. It mainly 
depends on the clinical presentation of the patients, like in depression (YMRS = 
3), euthymic (YMRS = 2) & in mania (YMRS = 12). Sometimes a clinical 
study entry requirement of YMRS > 20 generates a mean YMRS baseline of 
about 30. The advantage of YMRS includes, it is widely accepted, easy to 
administer and its brevity and its limitation includes,   it is mainly used in 
patients with the diagnosis of mania. YMRS is mainly used in the evaluation of 
symptoms of mania at the baseline and also during disease progression.  The 
time required for the administration of YMRS is usually 15-30 minutes and is 
routinely done by psychiatrists or any experts who trained in administering it. 
 
STATISTICAL METHODS 
The Statistical Package for Social Science (SPSS) version 16.0 was 
used for statistical analysis. For continuous variables Mean and standard 
deviation were calculated. For nominal and ordinal variables Frequencies 
with percentage were calculated. Chi-square and t- test/ANOVA were used 
for comparisons as applicable. 
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To assess the effect of independent variables on presence of metabolic 
syndrome, a binary logistic regression was performed. Pearson’s correlation test 
was employed to examine the relationship between illness parameters. A 
p=<0.05 was considered to be statistically significant. 
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Table - 1 :  Mean age of the sample: 
 
Age 
Mean  S.D t Df 
Statistical 
inference   
With Metabolic Syndrome 
(n=30) 
46.77 6.067 
6.588 59 
0.000<0.05 
Significant Without Metabolic 
Syndrome (n=31) 
33.29 9.480 
 
Study population was divided into two groups. Mean age of the Bipolar 
disorder patients with metabolic syndrome was found to be 46.77 ± 6.067 years. 
Mean age of Bipolar disorder patients without metabolic syndrome was found 
to be 33.29 ± 9.480.  
The difference between the two groups was statistically significant.  
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Table - 2: Age distribution of the sample. 
 
Age 
 
With 
metabolic 
syndrome 
(n=30) 
 
Without 
metabolic 
syndrome 
(n=31) 
 
Total  
(n = 61) 
 
15-30 YEARS 
 
2 (6.67%) 
 
11 (35.48%) 
 
13 (21.31%) 
 
31-45 YEARS 
 
12 (40%) 
 
17 (54.84%) 
 
29 (47.54%) 
 
46-60 YEARS 
 
16 (53.33%) 
 
3 (9.68%) 
 
19(31.15%) 
 
This table shows the age wise distribution of the sample. Mean age of the 
sample population was found to be 39.92 years. Most of the Bipolar disorder 
patients with metabolic syndrome fell in the age group between 46-60 years 
(53.33%) and Bipolar disorder patients without metabolic syndrome are in the 
age group between 31-45 years (54.84%).   
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Table - 3: Sex distribution of the sample. 
Sex 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Male 16 (53.3%) 16 (51.6%) 
32 
(52.5%) 
X2=.018 
 Df=1 
.893>0.05 
Not 
Significant 
 
Female 
14 (46.7%) 15 (48.4%) 
29 
(47.5%) 
 
This table illustrates the sex distribution of the sample. 47.5% of the total 
sample population were Females and 52.5% were males. There is no significant 
difference between two groups. 
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Table - 4: Religion distribution of the sample: 
Religion 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Hindu 26 (86.7%) 28 (90.3%) 
54 
(88.5%) 
X2=.201 
 Df=1 
.654>0.05 
Not Significant 
Non 
Hindu 
4 (13.3%) 3 (9.7%) 
7 
(11.5%) 
 
The above table shows the distribution of religion in the study population. 
It was found that around 88.5% of the total sample population were Hindus and 
11.5% were Non Hindus. 
The difference between the two groups with respect to religion was statistically 
not significant. 
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Table - 5: Educational status of the sample. 
Education 
With metabolic 
syndrome 
(n=30) 
 
Without 
metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
 Primary 11 (36.7%) 17 (54.8%) 
28 
(45.9%) 
X2=2.027 
 Df=1 
.154>0.05 
Not Significant 
Secondary & 
above 
19 (63.3%) 14 (45.2%) 
33 
(54.1%) 
 
The above table shows the Educational status of the study population. 
45.9% of the total study population had education up to primary level and 
54.1% of them had education more than primary (i.e., secondary & above).  
The difference between the two groups was statistically not significant. 
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Table - 6: Employment status of the sample: 
Employment 
status 
With 
metabolic 
syndrome 
(n=30) 
 
Without 
metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Working 19 (63.3%) 21 (67.7%) 
40 
(65.6%) 
X2=.131 
 Df=1 
.717>0.05 
Not 
Significant 
Not working 11 (36.7%) 10 (32.3%) 
21 
(34.4%) 
 
The above table describes the distribution of study population according 
to their employment status. Total number of persons employed in the sample 
was 40 (65.6%) and around 21 persons were unemployed (34.4%).  
No significant differences were made out between the two groups. 
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Table - 7: Locality of the sample: 
Locality 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Rural 24 (80.0%) 24 (77.4%) 
48 
(78.7%) 
X2=.061 
 Df=1 
.806>0.05 
Not 
Significant 
Urban 6(20.0%) 7 (22.6%) 
13 
(21.3%)  
 
The above table illustrates the distribution of sample based on their 
location. Among the sample 78.7% of patients were from rural background and 
21.3% were from urban areas. 
The difference between the two groups based on their location was not 
statistically significant. 
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Table - 8: Marital status of the sample: 
Marital 
status 
With metabolic 
syndrome 
(n=30) 
 
Without 
metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Married 26 (86.7%) 23 (74.2%) 
49 
(80.3%) 
X2=12.171 
 Df=2 
.002<0.05 
Significant 
Unmarried 0 (0%) 8 (25.8%) 
8 
(13.1%) 
Widow 4 (13.3%) 0 (.0%) 4 (6.6%) 
 
The above table shows the marital status of the sample.80.3% of the 
study population were married.13.1% were unmarried and they belong to 
Bipolar disorder patients without metabolic syndrome. 6.6% of the study 
syndrome. The difference between the two groups was statistically significant. 
 
population were widows and they belong to Bipolar disorder with metabolic 
  
 
 
 
 
FIGURE 3: MARITAL STATUS. 
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Table - 9: Dietary habits: 
Diet 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Veg 2 (6.7%) 4 (12.9%) 6 (9.8%) X
2
=.669  
Df=1 
.414>0.05 
Not 
Significant 
Non-
Veg 
28 (93.3%) 27 (87.1%) 
55 
(90.2%) 
 
The above table shows that around 90.2% of the study population were taking 
non vegetarian diet and around 9.8% people were taking vegetarian diet. 
The difference between the two groups was not statistically significant.
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Table: 10: Distribution of components of metabolic syndrome in sample: 
Parameters Numbers (n) Percentage (%) 
Abnormal waist 
circumference 
37 60.65 
Reduced HDL 22 35.3 
Increased triglyceride 18 29.5 
Increased BP 17 27.3 
Increased FBS 15 24.59 
 
 
The above table shows the distribution of abnormal metabolic parameters 
in the total sample population.  Waist circumference was the most common 
parameter altered and fasting sugar was the least common. Out of total 61 
patients thirty patients (49.18%) met the criteria for metabolic syndrome.  
 
  
 
 
 
FIGURE : 4 DISTRIBUTION OF COMPONENTS OF 
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A - Abnormal waist circumference 
B - Reduced HDL  
C - Increased triglyceride  
D - Increased BP  
E - Increased FBS  
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Table - 11: Anthropometric parameters of the sample: 
 
Anthropometric Parameters 
n(61) 
Minimum Maximum Mean SD 
WC(cm) 68 105 87.08 8.582 
BMI 18 31 24.18 3.462 
 
The above table shows the distribution of anthropometric parameters in 
the study population. The maximum waist circumference recorded in our 
sample was 105 cm and the minimal measurement was 68 cm. The average 
waist circumference of the total study population was 87.08±8.528.  
The average Body mass index of the total sample was 24.18±3.462.
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Table - 12: Biochemical parameters of the sample: 
 
Biochemical parameters 
n(61) 
Minimum Maximum Mean SD 
FBS(mg/dl) 68 119 96.43 14.151 
PPBS(mg/dl) 100 147 131.05 11.322 
HDL(mg/dL) 33 60 46.89 6.726 
TG(mg/dL) 115 158 142.30 10.364 
 
The above table illustrates the distribution of biochemical parameters in 
the study population. The average fasting blood sugar of the sample was 
96.43±14.151 and the postprandial blood sugar was 131.05±11.322. The lowest 
High Density Lipoprotein (HDL) value recorded was 33 with an average of 
46.89±6.726. The mean Triglyceride (TG) value of the sample was 
142.30±10.364.
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Table – 13: Thyroid profile of the sample: 
 
Thyroid profile 
n(61) 
Minimum Maximum Mean SD 
FT3 3 5 3.41 .580 
FT4 1 2 1.20 .345 
TSH 1 6 3.20 1.632 
 
The above table shows the distribution of thyroid profile in the total study 
population. On an average the free T3 in the sample was 3.14±0.580, free T4 
was found to be 1.20±0.345. The average TSH value of the sample was 
3.20±1.632.  
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Table - 14: Alcohol use in the sample: 
Alcohol 
use 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Yes 16 (53.3%) 11 (35.5%) 
27 
(44.3%) 
X2=1.969 
 Df=1 
.161>0.05 
Not 
Significant 
No 14 (46.7%) 20 (64.5%) 
34 
(55.7%) 
 
The above table shows the alcohol consumption in the study population. 
Around 27 (44.3%) persons in the sample were taking alcohol. Out of them 16 
persons (53.3%) qualified for metabolic syndrome. No significant differences 
between the two groups were made out in statistical analysis. 
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Table - 15: Alcohol abuse in the sample: 
Alcohol Abuse 
 
Mean  
 
S.D 
 
t 
 
Df 
 
Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
1.69 .479 
1.690 25 
.103>0.05 
Not 
Significant 
Without Metabolic 
Syndrome (N=31) 
1.36 .505 
 
The above table shows the alcohol abuse pattern in the total study 
population. On an average Bipolar disorder patients with metabolic syndrome 
had a mean of 1.69±0.479 and those without metabolic syndrome had a mean of 
1.36±0.505. The distribution was almost same for both groups and hence the 
difference was statistically not significant. 
51 
 
 
 
 
Table - 16: Alcohol dependence in the sample: 
Alcohol Dependence 
 
Mean  
 
S.D 
 
t 
 
df 
 
Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
1.56 .512 
-.850 25 
.403>0.05 
Not Significant Without Metabolic Syndrome 
(N=31) 
1.73 .467 
 
The above table shows the alcohol dependence pattern in the total study 
population. On an average Bipolar disorder patients with metabolic syndrome 
had a mean of 1.56±0.512 and those without metabolic syndrome had a mean of 
1.73±0.467. The distribution was almost same for both groups and hence the 
difference was statistically not significant 
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Table - 17: Index episode of the sample: 
Index 
episode 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Mania 21 (70.0%) 27 (87.1%) 
48 
(78.7%) 
X2=2.668 
 Df=2 
.263>0.05 
Not 
Significant 
Depression 7 (23.3%) 3 (9.7%) 
10 
(16.4%) 
Mixed 2 (6.7%) 1 (3.2%) 3 (4.9%) 
 
The above table shows the nature of the index episode of the study 
population. Majority had Mania as the first episode (n=48; 78.7%) followed by 
depressive episodes (n=10; 16.4%). 
The difference between the two groups was not statistically significant. 
  
 
 
 
FIGURE 6: INDEX EPISODE. 
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Table - 18: Total number of lifetime episodes: 
 
Mean  S.D T Df Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
6.47 1.224 
6.844 59 
.000<0.05 
Significant  Without Metabolic 
Syndrome (N=31) 
4.13 1.432 
 
The above table illustrates the total number of lifetime episodes in the 
study population. On an average Bipolar disorder patients with metabolic 
syndrome had a mean of 6.47 and those without metabolic syndrome had a 
mean of 4.13 lifetime episodes. 
The difference between the two groups was statistically significant. 
  
 
 
 
 
FIGURE 7: TOTAL NO. OF EPISODES 
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Table - 19: Total number of lifetime manic episodes: 
 
Mean  S.D t Df Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
3.57 1.194 
3.219 59 
.002<0.05 
Significant  Without Metabolic 
Syndrome (N=31) 
2.71 .864 
 
The above table shows the total number of lifetime manic episodes in the 
study population. On an average Bipolar disorder patients with metabolic 
syndrome had a mean of 3.57 and those without metabolic syndrome had a 
mean of 2.71 lifetime manic episodes. 
The difference between the two groups was statistically significant.
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Table - 20: Total number of lifetime depressive episodes: 
 
Mean  S.D t Df Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
2.70 1.557 
4.110 59 
.000<0.05 
Significant  Without Metabolic Syndrome 
(N=31) 
1.23 1.230 
 
The above table shows the total number of lifetime depressive episodes in 
the study population. On an average Bipolar disorder patients with metabolic 
syndrome had a mean of 2.70 and those without metabolic syndrome had a 
mean of 1.23 lifetime depressive episodes. 
The difference between the two groups was statistically significant. 
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Table - 21: Total number of lifetime mixed episodes: 
 
Mean  S.D t Df Statistical 
inference  
With Metabolic Syndrome 
(N=30) 
.20 .484 
.049 59 
.961>0.05 
Not Significant Without Metabolic Syndrome 
(N=31) 
.19 .543 
 
The above table shows the total number of lifetime mixed episodes in the 
study population. On an average Bipolar disorder patients with metabolic 
syndrome had a mean of 0.20 and those without metabolic syndrome had a 
mean of 0.19 lifetime mixed episodes. 
The difference between the two groups was statistically not significant. 
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Table - 22: Age at onset of Bipolar disorder: 
Age at onset Mean  S.D t df 
Statistical 
inference   
With Metabolic Syndrome 
(N=30) 
25.23 2.112 
.260 59 
.796>0.05 
Not Significant Without Metabolic 
Syndrome (N=31) 
25.06 2.886 
 
The above table illustrates the age of onset of Bipolar disorder in the 
study population.  The age at onset of the illness in Bipolar disorder patients 
with metabolic syndrome was found to be 25.23±2.112 and for those without 
metabolic syndrome was 25.06±2.886. 
The difference between the two groups was not statistically significant.
  
 
 
 
FIGURE 8: AGE AT ONSET. 
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Table - 23: Nature of the current episode: 
current 
episode 
With metabolic 
syndrome 
(n=30) 
 
Without metabolic 
syndrome 
(n=31) 
 
Total 
(n=61) 
Statistical 
inference 
Mania 14 (46.7%) 20 (64.5%) 
34 
(55.7%) 
X2=1.969  
Df=1 
.161>0.05 
Not 
Significant 
Depression 16 (53.3%) 11 (35.5%) 
27 
(44.3%) 
 
The above table depicts the nature of the current episode in the study 
population. Majority had manic episodes (55.7%). Around 27 (44.3%) persons 
had depressive episodes. No mixed episodes have been reported. 
The difference between the two groups was statistically not significant.
  
 
 
 
 
FIGURE 9: CURRENT EPISODE. 
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Table - 24: Comparison of Young Mania Rating Scale total scores 
between Bipolar disorder with metabolic syndrome and Bipolar disorder 
without metabolic syndrome: 
YMRS 
Mean Total 
YMRS scores  
S.D T df Statistical 
inference  
With Metabolic 
Syndrome (N=30) 
6.87 7.628 
-2.693 59 
.009<0.05 
Significant  Without Metabolic 
Syndrome (N=31) 
13.06 10.129 
 
This table shows that mean total YMRS scores are higher in Bipolar 
disorder patients without metabolic syndrome (13.06±9.10.129) compared to 
those with metabolic syndrome (6.87±7.628). 
The difference between the two groups was statistically significant 
  
 
 
 
FIGURE 10: COMPARISON YOUNG MANIA RATING 
SCALE TOTAL SCORES  
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Table - 25: Comparison of Hamilton Depression Rating Scale total scores 
between Bipolar disorder with metabolic syndrome and Bipolar disorder 
without metabolic syndrome: 
HAMD 
Mean Total 
HAMD scores  
S.D T Df Statistical 
inference  
With Metabolic 
Syndrome (N=30) 
9.53 9.261 
2.361 59 
.022<0.05 
Significant  Without Metabolic 
Syndrome (N=31) 
4.71 6.497 
 
This table shows that mean total HAMD scores are higher in Bipolar 
disorder patients with metabolic syndrome (9.53±9.261) compared to those 
without metabolic syndrome (4.71±6.497). 
The difference between the two groups was statistically significant. 
  
 
 
FIGURE 11: COMPARISON HAMILTON DEPRESSION  
                 RATING SCALE TOTAL SCORES  
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DISCUSSION 
In the present study we examined 61 patients with the diagnosis of 
Bipolar disorder who attended department of psychiatry of Thanjavur medical 
college hospital. We conducted a detailed physical examination and clinical 
assessment. Patients were assessed for the metabolic abnormalities like obesity, 
hypertension, diabetes mellitus, dyslipidemia, and thyroid functions. Our aim 
was to assess the extent to which these metabolic abnormalities are present in 
the given sample and delineate as to how many of them qualify for a diagnosis 
of metabolic syndrome. In addition we wanted to discern the relationship 
between metabolic syndrome and the severity of the present state as well as the 
course variables of Bipolar disorder. 
 
 Studies from west have concluded that the metabolic syndrome and its 
components are interwoven with the disease progression and appear to be 
powerful determinants of the course of Bipolar disorder.
24, 58
 The linkages 
between metabolic syndrome and Bipolar disorder have not been explored in 
Indian context despite growing rates of early onset of diabetes mellitus and 
hypertension. In the present study in addition to examining the prevalence of 
metabolic syndrome in Bipolar patients an effort has been made to explore its 
relationship with the type of index episode, total numbers of life time episodes, 
and severity of the current episode. This particular aspect hasn’t received 
attention in the Indian context. 
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SOCIODEMOGRAPHIC VARIABLES 
AGE AND METABOLIC SYNDROME IN BIPOLAR DISORDER 
The patients of Bipolar disorder with Metabolic syndrome were found to 
be much older than patients with Metabolic syndrome alone.
145,155,156,157
 A 
review of 34 studies
24
 across the world shows prevalence ranging from 16.7 to 
67% with a mean age ranging from 34.1 to 55.7 years. A recent meta-analytic 
investigation
58
 (33 studies, N=6,286) revealed that the prevalence of Metabolic 
syndrome across studies was 37.3% with a mean age of 42.8 years. Study by 
Grover et al, which was the first of its kind regarding this aspect in Indian 
context, reported a prevalence of 41% metabolic syndrome in patients of 
Bipolar disorder with mean age of 39 years. In our study the mean age of 
patients of Bipolar disorder with Metabolic syndrome  is 46.77±6.07 years as 
compared to these Bipolar patients without Metabolic syndrome  (33.29±9.4 
years) and the prevalence was 49.18%. These findings are consistent with the 
existing literature. 
 
GENDER AND METABOLIC SYNDROME IN BIPOLAR DISORDER 
Studies which analysed the age adjusted prevalence158, 159 of Metabolic 
syndrome with regard to gender in Bipolar disorder give variable findings. The 
prevalence of metabolic syndrome  was less in European women as compared to 
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men (14.4%Vs 18.4%), while South Asian men were having lesser rate of 
metabolic syndrome  as compared to women (28.8%Vs 31.8%). Studies 
conducted in United States also show a higher prevalence of Metabolic 
syndrome  in women (23.7% Vs 15.7%). Grover et al
24
 in his study reported 
that 61 men and 21 women satisfied the modified NCEP ATP-III criteria,
49
 
which thus showed the prevalence of metabolic syndrome  was higher in men 
(43.57% Vs 35%). In our study 16 men and 14 women met the criteria (53.34% 
Vs 46.67%) for metabolic syndrome showing a higher prevalence of metabolic 
syndrome in men than in women which is in tune with the above Indian study.  
Other socio-demographic variables like religious background, 
employment status and place of stay were quite comparable to those reported by 
Grover et al.
24
 
 
 
PREVALENCE OF METABOLIC ABNORMALITIES 
OBESITY 
Overweight, obesity and extreme obesity were found to be common in 
patients with Bipolar disorder
12
.The prevalence of overweight and obesity in the 
patient of Bipolar disorder is reported
18
 to be 20-35%. Majority of the studies 
use the Body Mass Index (BMI) >30 as cut off to define obesity while in our 
study we define obesity when the BMI >25 and overweight when the BMI>23. 
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This is based on the modified criteria of obesity for Asian population by 
WHO.
10
 Studies done in the west
24
 report that BMI ranges between 30.4 and 
46.5. Grover S et al.
160
 reported that the average BMI was 25.91 among Bipolar 
disorder patients and it was higher in women compared to men. While the 
average BMI in our sample was 24.18. It was similar to the above mentioned 
study.  
The waist circumference (WC) is the measurement of abdominal fat and 
an easily measurable component of metabolic syndrome. High waist 
circumference is seen commonly in Bipolar patients as compared to age 
matched control group.
7
 In their review Grover et al
24
 report that the prevalence 
of waist circumference ranges 30% to 61% among Bipolar disorder patients. 
There was a higher prevalence in the present study (60.65%) with waist 
circumference being more among men compared to women. While BMI offers 
the best estimate of total body fat, waist circumference gives an estimate of 
visceral fat and risk of obesity related diseases.  
Studies suggest that high BMI is associated with greater number of 
lifetime depressive and manic episodes and difficult to treat index episode, in 
addition to a high recurrence rate for depressive episodes.
5
 In our study we did 
not find a significant correlation between the higher BMI and the total numbers 
of life time episodes but there was a strong correlation between waist 
circumference and the number of mixed episodes. However the number of 
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patients with mixed episode was not high in the sample and this finding is 
merely an indicative one. There was also a correlation between age and waist 
circumference (p=0.016) with older patient having more abdominal fat. 
 
HYPERTENSION 
Patients with Bipolar disorder have a high prevalence of hypertension and 
increased risk of mortality due to cardiovascular disease.
17-19
 In their review 
Grover et al
24
 report that the prevalence of hypertension in patients of Bipolar 
disorder ranges from 18.6% to 78.1%. In the present study 27.3% patients were 
hypertensive which is within the range reported in the literature. However the 
role of antihypertensive medications in modulating the prevalence has to be 
taken into consideration. 
 
DYSLIPIDEMIA 
Studies across the world show a high prevalence of dyslipidemia in 
patients of Bipolar disorder.
7
 In a recent review of 34 studies Grover et al
24
 
report that the prevalence of low HDL level across the 19 studies was ranging 
from 21.7% to 67.6% and high triglyceride range from 22.7% to 58.8%. In the 
present study 35.3% of patients were having low HDL level while 29.50% were 
having high triglyceride level. These findings are again consistent with the 
previous studies. 
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DIABETES MELLITUS 
Impaired glucose tolerances and insulin resistance is found to be more 
common in individuals with Bipolar disorder than in the general population.
31 
Grover et al
24
 reported that the prevalence of high fasting blood sugar across 19 
studies ranges from 6% to 32.4%. In the present study 24.59% patients were 
having high FBS which is in tune with the findings in the literature. 
 
THYROID ABNORMALITIES 
In view of the extensive metabolic effect of thyroid hormone and its close 
relation with mood disorders
41
 we examined thyroid functions and found that 
higher TSH level (>5mU/mL) was seen in 28% patients. Overt or subclinical 
hypothyroidism has been associated with metabolic risk factors, including 
cardiovascular disease and dyslipidemia.
42-45 
Abnormal thyroid function also has 
been linked to slower response to acute treatment and poor quality of long term 
remission in Bipolar patients.
46
 
PREVALENCE OF METABOLIC SYNDROME 
Metabolic syndrome, which is a constellation of metabolic abnormalities, 
associated with development of coronary heart disease,
48,49 
as the available data 
suggest that cardiovascular disease is the most common cause of excess and 
premature mortality in Bipolar disorder patients.
17-19
 Prevention, identification, 
and modification of the cardiovascular risk factors should be one of the 
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important therapeutic objectives in the managements of Bipolar disorder. The 
studies across different countries
24
 reported the prevalence of metabolic 
syndrome in the range of 16.7% to 67%. The study from India revealed a 
prevalence of 41%. Present study gives a prevalence of 49.18 % which fall 
within the range. 
 
COMPONENTS OF METABOLIC SYNDROME 
Metabolic syndrome comprises of both anthropometric and metabolic 
parameters. Studies from the West indicate waist circumference (WC) to be the 
most common abnormality
24
 (30- 85%) with high fasting blood sugar (FBS) 
being least common (6-43.5%), Lipid abnormalities were intermediate in 
prevalence. In the present study abnormal waist circumference was seen in 
60.65% patients (n=37) followed by low HDL level (35.3%), high triglyceride 
(29.50%), high blood pressure (27.3%) with high fasting blood sugar (FBS) 
being least common 24.59% . Unlike Grover.S et al.
160 
study which reported 
high blood pressure to be the second most common metabolic parameter in 
metabolic syndrome, in the present investigation increased triglyceride and low 
HDL were more prevalent than increased blood pressure. These findings 
indicate that there could be variations across and within nations. 
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CLINICAL COREELATES OF METABOLIC SYNDROME IN 
BIPOLAR DISORDER 
Metabolic syndrome has an impact on the course of Bipolar disorder. 
Presence of metabolic syndrome is reported to be associated with greater 
numbers of manic and depressive episodes.
146,6 
longer duration of illness,
144,145 
more frequent Bipolar I disorder,
144
 more frequent depressive episode at 
onset,
147
 difficult to treat index episodes
146,6
 and lesser severity of index manic 
episode.
156 
Lag period to treatment was more among patients with metabolic 
syndrome .
149
 An attempt was made in the present investigation to explore the 
association of salient clinical variables with metabolic syndrome . It was found 
that patients of Bipolar disorder  with metabolic syndrome  had more number of 
total life time episodes as compared with the patients without metabolic 
syndrome  (6.47±1.2 Vs 4.13±1.4), a longer duration of illness (15.36 Vs 10.16 
yrs), and a greater frequency of type I Bipolar disorder. These patients reported 
a higher frequency of depressive episode at onset of illness (23.3% Vs 9.7%). In 
addition the severity of current episode as assessed by the relevant scales 
showed that depressive episodes were more severe (9.53±9.261 Vs 4.71±6.497) 
and manic episodes were of lesser severity (6.87±7.628 Vs 13.06±10.129). The 
lag period to treatment among patients with metabolic syndrome was found to 
be longer (82.9±221 Vs 63.9±260). These findings of clinical correlates of 
metabolic syndrome in Bipolar disorder are consistent with the previous studies. 
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In addition to the above clinical correlates, in the present study the frequency of 
depressive episodes were found to be significantly higher in the patients with 
Bipolar disorder  with metabolic syndrome  (2.7±1.5Vs 1.23±1.23; p=0.008). 
The interplay between depression and metabolic syndrome is mediated through 
multiple mechanisms and a bidirectional association is most likely. 
 
SUBSTANCE USE AND METABOLIC SYNDROME IN BIPOLAR 
DISORDER 
Substance abuse disorders had been demonstrated to have higher 
incidence in Bipolar disorder patients than in general population. In general 
population the incidence was 12.8%; but in Bipolar disorder it is shown to be 
significantly higher at 35.3% (108) (NESARC; study on 43093 respondents). 
They also demonstrated the 12-month prevalence of substance use disorders, 
which was about 27.9% in mania patients and 26.6% in hypomania; but the same 
was only 9.4% in the general population (108).   
In another study (109) on Bipolar disorder patients nicotine dependency 
was significantly higher at 70%; and use / abuse of alcohol was also greater than 
the general population. In another study the alcohol use in Bipolar disorder patients 
was reported to be 21.4 to 54.5% (110).   
In the present study we found that 27 patients (44.37%) had history of 
alcohol use, with 10 patients (16.4%) being dependent on it. All alcohol users 
were also found to use nicotine in various forms. We did not find any 
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association between substance use, abuse and dependence with metabolic 
syndrome in the present sample. On the other hand increased triglyceride level 
(p=0.013) increased total cholesterol (p=0.044), and increased systolic blood 
pressure (p=0.039), were common among alcohol users. 
 
PREDICTORS OF METABOLIC SYNDROME IN BIPOLAR 
DISORDER 
Multiple factors affect the occurrence of metabolic syndrome in Bipolar 
patients. Western studies suggest that longer duration illness
144,145
 and age more 
than 35 years can be a strong predictor for the development of metabolic 
syndrome , which has been replicated by Grover et al
160
 in the Indian context. A 
binary logistic regression analysis was carried out to identify predictors of 
metabolic syndrome in the present study. Age, number of lifetime depressive 
episodes and more total number of lifetime episodes are significant predictors.  
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CONCLUSIONS 
The present study is a cross sectional study done on 61 patients with a 
diagnosis of Bipolar Affective Disorder with a view to examine the presence of 
Metabolic Syndrome and its clinical correlates. The study was conducted in a 
general hospital psychiatric unit. 
A detailed clinical history was taken using a life chart. Anthropometric 
measurements were taken, relevant biochemical investigations to assess 
metabolic changes were done and the severity of the current clinical episode 
was assessed using relevant scales. 
The study findings revealed that: 
1. The mean age of the study population was 39 years. More than half of 
them were males, majority of them being from rural areas, educated up to 
secondary level. Half of the population were employed, with women 
being mainly housewives. Majority were Hindus.         
2.  The prevalence of metabolic syndrome was 49.18% in the given sample.                
3. Waist circumference was the most common abnormal anthropometric 
parameter in these patients (60.65%).   
4. Low HDL level was seen in 35.3%.     
5. High triglyceride level was found in 29.5%.    
6. High blood pressures were recorded in 27.3% with high fasting blood 
sugars in 24.59%.     
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7. The use of alcohol was significantly associated with various metabolic 
abnormalities like increased triglyceride (p=0.013), increased total 
cholesterol (p=0.044), and increased systolic blood pressure (p=0.039). 
8. Patients of Bipolar disorder with metabolic syndrome  were found to have 
a greater number of life time episodes, longer duration of illness, more 
frequent association of Bipolar type I disorder, onset of illness with a 
depressive episode, greater numbers of lifetime depressive episodes 
(p=0.008) more severe index depressive episode and a lesser severity of 
index manic episode.      
9. Age of the patients, number of lifetime depressive episodes and more 
total number of lifetime episodes were found to be associated with the 
development of metabolic syndrome. 
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SUMMARY 
 
The Metabolic syndrome has a strong association with Bipolar disorder, 
with an adverse effect on the course of the illness. The main components of the 
metabolic syndrome can be detected and modified easily. Early identification 
and intervention for the same could affect the course of Bipolar disorder 
favourably as well as reduce the mortality and morbidity associated with it. The 
present study is carried out with the objectives to examine the extent and the 
impact of metabolic syndrome on Bipolar disorder. 
 
A cross sectional study was done on 61 consecutive patients with a 
diagnosis of Bipolar Affective Disorder, attending the psychiatry department, 
Thanjavur medical college hospital, recruited by purposive sampling method for 
a period of six months. 
 
The patients were screened for various anthropometric and metabolic 
abnormalities by using standard methods. The severity of the present symptoms 
was assessed by appropriate rating scales. The diagnosis of metabolic syndrome 
was derived by adopting a standardized consensus definition. 
 
The mean age of the study population was 39 years. More than half of 
them were males, majority of them being from rural areas, educated up to 
secondary level. Half the population were employed, with women being mainly 
housewives. Majority were Hindus. 
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The criteria for the metabolic syndrome were satisfied by 49.18% of 
patients. The prevalence was seen to increase with age, and was higher in the 
male patients. The various components of metabolic syndrome were also found 
to be high. 64% patients were obese, 60.65% were having abdominal obesity, 
hypertension was present in 27.3%, low HDL found in 35.3%, increased 
triglyceride present in 29.5%, and increased fasting blood sugar was present in 
24.59%.  44.3% were using alcohol. Thyroid function abnormalities were 
detected in 28%. Patients with increased abdominal obesity were found to have 
more mixed episodes (p=0.015). 
 
Patients of Bipolar disorder with metabolic syndrome were found to have a 
greater number of lifetime episodes, longer duration of illness, more frequent 
depressive episodes at onset, and a more severe index depressive episode. The 
lag period to treatment was more and the index manic episode was of lesser 
severity. The life time depressive episodes were significantly higher in them 
(p=0.008). 
 
Increasing age, more number of lifetime depressive episodes and the more 
total number of lifetime episodes appear to be predictors for the occurrence of 
metabolic syndrome in patients with Bipolar disorder. We thus have valuable  
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insight about the relationship between metabolic syndrome and Bipolar disorder.  
The presence of metabolic syndrome influences the course and severity of the 
illness. It is possible to detect the presence of the metabolic syndrome and its 
components in the early stages of their development and plan timely 
intervention. This would help in altering the course and severity of the illness in 
a favourable manner. 
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IMPLICATIONS 
1. Considering the high prevalence of metabolic syndrome in the patients of 
Bipolar disorder, strategies have to be developed for prevention, early 
detection and treatment of the same.   
2. Patients need to be assessed on risk factors for a metabolic syndrome 
based on family history, personal history, relevant anthropometric 
measurements and biochemical investigations.  
3. Appropriate psychoeducation regarding a healthy lifestyle, physical 
activity, and a healthy diet, can be provided to all the patients as a regular 
protocol which can prevent the occurrence of metabolic syndrome. 
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LIMITATIONS 
1. The current study being a cross sectional one in design, has its own 
limitations. The sample size being small, and the study being based in a 
general hospital setting, makes generalization difficult. 
2. Recall biases may affect the precision of information about the previous 
episodes, especially medication details. 
3. Lack of control group makes it difficult to comment about the effect of 
psychosocial factors. 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
STRENGTH OF THE STUDY 
1. The present study has covered some of the issues that the previous studies 
have not examined.   
2. The effects of substance use, and the correlation of the metabolic 
syndrome with the clinical presentation of Bipolar disorder, have been 
looked into.  
3. The association of clinical variables impacting metabolic syndrome in 
Bipolar patients hasn’t received adequate attention in the Indian context. 
4. By demonstrating their significant associations of metabolic syndrome, 
the present investigation sets the stage for further specific enquiries into 
this important area. 
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 ANNEXURE - I 
Consent form: 
தகவ அறி	 ஆவி பேகபதகான ஒத: 
 
 
……........................................ ஆகிய நா மனேசா / மனஎசி ேநா ம ! 
வளசிைத மாற ேநா$%றி இைடயிலான ெதாடைப அறிவதகான 
ஆவி பேகக * மன	ட ச!மதி$கிேற,  
இத ஆவி ேநா$க+ைத ம,+	வ-டமி,	 அறி	 ெகா.ேட. நா 
அளி$%! தகவக0 ரகசியமாக கா$கப2! எ  அறிேவ.  
என$% வி,பமிைலெயனி எத ேநர+தி3! விலகி$ெகா0ளலா! எ  
அறிேவ, 
 
 
ம,+	வ- ைகெயாப!                    ேநாயாளி / காபாள- ைகெயாப! 
 
 
ேததி: 
 
*கவ-: 
ANNEXURE – II 
 
Patient’s Socio-Demographic & Clinical Profile: 
 
1. Age:  ..................years 
 
2. Sex:  Male / Female 
 
3. Education: 
 
4. Occupation:    Employed / Unemployed 
 
5. Marital status:  Married / Never married / Separated-Divorced / Widow 
 
6. Locality   :   Rural / Urban 
 
7. Dietary Habit:  Veg / Non-veg / Egg 
 
Patient’s clinical profile: 
1. Age at onset 
2. Nature of the Index episode: Mania/ Depression/Mixed 
3. Total number of lifetime episodes 
4. Total number of lifetime manic episodes 
5. Total number of lifetime depressive episodes 
6. Total number of lifetime mixed episodes 
7. Nature of the current episode: Mania/ Depression/Mixed 
8. Severity of the current episode: 
YMRS total score(in Mania): 
HAMD  total score(in Depression): 
 
9. Alcohol use:  use/abuse/dependence 
ANNEXURE – III 
 
YOUNG MANIA RATING SCALE (YMRS) 
 
1. Elevated Mood 
0 Absent 
1 Mildly or possibly increased on questioning 
2 Definite subjective elevation; optimistic, self-confident; cheerful; appropriate to 
content 
3 Elevated; inappropriate to content; humorous 
4 Euphoric; inappropriate laughter; singing 
 
2. Increased Motor Activity-Energy 
0 Absent 
1 Subjectively increased 
2 Animated; gestures increased 
3 Excessive energy; hyperactive at times; restless (can be calmed) 
4 Motor excitement; continuous hyperactivity (cannot be calmed) 
 
3. Sexual Interest 
0 Normal; not increased 
1 Mildly or possibly increased 
2 Definite subjective increase on questioning 
3 Spontaneous sexual content; elaborates on sexual matters; hypersexual by 
self-report 
4 Overt sexual acts (toward patients, staff, or interviewer) 
 
4. Sleep 
0 Reports no decrease in sleep 
1 Sleeping less than normal amount by up to one hour 
2 Sleeping less than normal by more than one hour 
3 Reports decreased need for sleep 
4 Denies need for sleep 
 
5. Irritability 
0 Absent 
2 Subjectively increased 
4 Irritable at times during interview; recent episodes of anger or annoyance on ward 
6 Frequently irritable during interview; short, curt throughout 
8 Hostile, uncooperative; interview impossible 
 
 
 
6. Speech (Rate and Amount) 
0 No increase 
2 Feels talkative 
4 Increased rate or amount at times, verbose at times 
6 Push; consistently increased rate and amount; difficult to interrupt 
8 Pressured; uninterruptible, continuous speech 
 
7. Language-Thought Disorder 
0 Absent 
1 Circumstantial; mild distractibility; quick thoughts 
2 Distractible, loses goal of thought; changes topics frequently; racing thoughts 
3 Flight of ideas; tangentiality; difficult to follow; rhyming, echolalia 
4 Incoherent; communication impossible 
 
8. Content 
0 Normal 
2 Questionable plans, new interests 
4 Special project(s); hyper-religious 
6 Grandiose or paranoid ideas; ideas of reference 
8 Delusions; hallucinations 
 
9. Disruptive-Aggressive Behaviour 
0 Absent, cooperative 
2 Sarcastic; loud at times, guarded 
4 Demanding; threats on ward 
6 Threatens interviewer; shouting; interview difficult 
8 Assaultive; destructive; interview impossible 
 
10. Appearance 
0 Appropriate dressing and grooming 
1 Minimally unkempt 
2 Poorly groomed; moderately dishevelled; overdressed 
3 Dishevelled; partly clothed; garish make-up 
4 Completely unkempt; decorated; bizarre garb 
 
11. Insight 
0 Present; admits illness; agrees with need for treatment 
1 Possibly ill 
2 Admits behaviour change, but denies illness 
3 Admits possible change in behaviour, but denies illness 
4 Denies any behaviour change 
 
 
 ANNEXURE – IV 
 
HAMILTON RATING SCALE FOR DEPRESSION (HAM-D) 
 
For each item, write the correct number on the line next to the item. (Only one 
response per item) 
 
1. DEPRESSED MOOD (Sadness, hopeless, helpless, worthless) 
0= Absent 
1= These feeling states indicated only on questioning 
2= These feeling states spontaneously reported verbally 
3= Communicates feeling states non-verbally—i.e., through facial expression, posture, 
voice, and tendency to weep 
4= Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal 
and non-verbal communication 
 
2. FEELINGS OF GUILT 
0= Absent 
1= Self reproach, feels he has let people down 
2= Ideas of guilt or rumination over past errors or sinful deeds 
3= Present illness is a punishment. Delusions of guilt 
4= Hears accusatory or denunciatory voices and/or experiences threatening visual 
Hallucinations 
 
3. SUICIDE 
0= Absent 
1= Feels life is not worth living 
2= Wishes he were dead or any thoughts of possible death to self 
3= Suicidal ideas or gesture 
4= Attempts at suicide (any serious attempt rates 4) 
 
4. INSOMNIA EARLY 
0= No difficulty falling asleep 
1= Complains of occasional difficulty falling asleep—i.e., more than 1/2 hour 
2= Complains of nightly difficulty falling asleep 
 
5. INSOMNIA MIDDLE 
0= No difficulty 
1= Patient complains of being restless and disturbed during the night 
2= Waking during the night—any getting out of bed rates 2 (except for purposes of 
voiding) 
 
 
 6. INSOMNIA LATE 
0= No difficulty 
1= Waking in early hours of the morning but goes back to sleep 
2= Unable to fall asleep again if he gets out of bed 
 
7. WORK AND ACTIVITIES 
0= No difficulty 
1= Thoughts and feelings of incapacity, fatigue or weakness related to activities; work 
or hobbies 
2= Loss of interest in activity; hobbies or work—either directly reported by patient, or      
indirect in listlessness, indecision and vacillation (feels he has to push self to work or      
activities) 
3= Decrease in actual time spent in activities or decrease in productivity 
4= Stopped working because of present illness 
 
8. RETARDATION: PSYCHOMOTOR  
(Slowness of thought and speech; impaired ability to concentrate; decreased motor 
activity) 
0= Normal speech and thought 
1= Slight retardation at interview 
2= Obvious retardation at interview 
3= Interview difficult 
4= Complete stupor 
 
9. AGITATION 
0= None 
1= Fidgetiness 
2= Playing with hands, hair, etc. 
3= Moving about, can’t sit still 
4= Hand wringing, nail biting, hair-pulling, biting of lips 
 
10. ANXIETY (PSYCHOLOGICAL) 
0= No difficulty 
1= Subjective tension and irritability 
2= Worrying about minor matters 
3= Apprehensive attitude apparent in face or speech 
4= Fears expressed without questioning 
 
11. ANXIETY SOMATIC: Physiological concomitants of anxiety, (i.e., effects of 
autonomic over activity, “butterflies,” indigestion, stomach cramps, belching, diarrhea, 
palpitations, hyperventilation, paresthesia, sweating, flushing, tremor, headache, 
urinary frequency).Avoid asking about possible medication side effects (i.e., dry 
mouth, constipation) 
0= Absent 
1= Mild 
2= Moderate 
3= Severe 
4= Incapacitating 
 
12. SOMATIC SYMPTOMS (GASTROINTESTINAL) 
0= None 
1= Loss of appetite but eating without encouragement from others. Food intake about 
normal 
2= Difficulty eating without urging from others. Marked reduction of appetite and 
food intake 
 
13. SOMATIC SYMPTOMS GENERAL 
0= None 
1= Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of 
energy and fatigability 
2= Any clear-cut symptom rates 2 
 
14. GENITAL SYMPTOMS (Symptoms such as: loss of libido; impaired sexual   
performance; menstrual disturbances) 
0= Absent 
1= Mild 
2= Severe 
  
15. HYPOCHONDRIASIS 
0= Not present 
1= Self-absorption (bodily) 
2= Preoccupation with health 
3= Frequent complaints, requests for help, etc. 
4= Hypochondriacal delusions 
 
16. LOSS OF WEIGHT 
A. When rating by history: 
0= No weight loss 
1= Probably weight loss associated with present illness 
2= Definite (according to patient) weight loss 
3= Not assessed 
 
17. INSIGHT 
0= Acknowledges being depressed and ill 
1= Acknowledges illness but attributes cause to bad food, climate, overwork, virus, 
need for rest, etc. 
2= Denies being ill at all. 
18. DIURNAL VARIATION 
A. Note whether symptoms are worse in morning or evening. If NO diurnal variation, 
mark none 
0= No variation 
1= Worse in A.M. 
2= Worse in P.M. 
  
B. When present, mark the severity of the variation. Mark “None” if NO variation 
0= None 
1= Mild 
2= Severe 
 
19. DEPERSONALIZATION AND DEREALIZATION (Such as: Feelings of 
unreality; Nihilistic ideas) 
0= Absent 
1= Mild 
2= Moderate 
3= Severe 
4= Incapacitating 
 
20. PARANOID SYMPTOMS 
0= None 
1= Suspicious 
2= Ideas of reference 
3= Delusions of reference and persecution 
 
21. OBSESSIONAL AND COMPULSIVE SYMPTOMS 
0= Absent 
1= Mild 
2= Severe 
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Ma
n
i
a
D
e
p
r
e
s
s
i
o
n
M
i
x
e
d
T
o
t
a
l
c
u
r
r
e
n
t
 
e
p
i
s
o
d
e
Y
M
R
S
H
A
M
D
U
s
e
A
b
u
s
e
D
e
p
e
n
d
e
n
c
e
1 49 M H 1 2 1 2 2 94 23 120/90 110 140 34 150 4 2 5 49 23 2 4 3 0 7 2 0 14 1 1 2
2 52 M H 1 2 1 2 2 98 24 120/80 116 142 36 148 5 2 6 52 22 2 4 4 0 8 2 0 15 1 1 2
3 48 M H 1 2 1 2 2 96 25 126/88 111 141 39 142 4 2 5 48 23 2 3 3 0 6 1 11 0 1 1 2
4 44 M H 1 2 1 2 2 101 29 128/90 114 142 44 155 4 2 6 44 24 2 3 2 0 5 1 14 0 1 2 1
5 45 M H 1 2 1 2 2 87 26 130/90 105 144 38 143 4 2 5 45 25 1 2 3 0 5 1 12 0 1 2 1
6 49 M H 3 2 1 1 2 96 29 134/86 103 136 40 148 4 2 5 49 26 1 3 2 1 6 1 16 0 1 2 2
7 43 M NH 1 2 1 2 1 99 28 132/88 109 139 41 151 3 1 2 43 21 3 3 1 1 5 2 0 17 1 2 2
8 45 M H 1 2 1 2 2 100 28 135/86 112 140 39 147 3 1 2 45 27 1 2 4 0 6 1 14 0 1 2 1
9 42 M H 1 2 1 2 2 97 27 130/90 104 137 33 146 3 1 4 42 25 1 3 2 0 5 2 0 18 1 2 1
10 44 M H 1 2 1 1 2 99 25 130/90 109 142 34 149 3 1 4 44 21 3 3 2 1 6 1 17 0 1 1 2
11 50 M NH 1 2 1 2 2 103 29 138/90 115 141 35 151 3 1 4 50 26 1 4 3 0 7 2 0 16 1 1 2
12 30 M H 1 2 1 2 2 88 23 138/92 112 139 38 155 4 1 2 30 25 1 4 1 0 5 1 11 0 1 2 1
13 46 M H 1 1 2 1 2 94 23 140/86 119 135 42 149 3 1 1 46 27 1 5 2 1 8 1 14 0 1 2 1
14 49 M H 3 1 2 2 2 92 22 140/90 107 140 40 150 3 1 1 49 26 1 4 3 0 7 2 0 17 1 2 2
15 47 M H 1 1 2 2 2 96 24 136/88 108 143 39 154 3 1 2 47 28 1 4 2 0 6 2 0 19 1 2 2
16 45 M H 1 2 1 1 2 105 30 136/86 107 142 38 157 4 1 2 45 25 1 3 4 0 7 2 0 21 1 2 1
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17 45 F H 1 1 2 2 1 86 28 136/90 111 132 49 145 4 1 3 45 29 1 5 1 0 6 2 0 19 2
18 51 F H 1 2 1 2 2 88 29 130/94 112 136 48 146 3 1 3 51 26 1 5 3 0 8 1 18 0 2
19 30 F NH 1 2 1 2 2 78 22 136/90 113 137 47 153 3 2 4 30 25 1 3 1 0 4 1 14 0 2
20 48 F H 1 1 2 2 2 83 28 130/90 109 140 53 149 4 1 4 48 26 1 1 5 0 6 2 0 20 2
21 54 F H 3 1 2 1 2 91 26 135/88 108 142 54 140 4 2 3 54 28 1 4 2 2 8 1 15 0 2
22 56 F H 3 2 1 2 2 85 24 130/90 107 143 57 139 3 1 3 56 27 1 1 8 0 9 1 15 0 2
23 45 F H 1 2 1 1 2 94 22 138/86 106 132 49 142 3 1 2 45 25 1 4 2 0 6 2 0 19 2
24 44 F H 1 2 1 2 2 82 25 140/90 114 139 45 146 3 2 1 44 26 1 5 2 0 7 2 0 21 2
25 53 F H 1 1 2 2 2 89 27 135/90 113 142 47 150 3 1 1 53 25 1 2 6 0 8 2 0 23 2
26 43 F H 1 2 1 2 2 85 24 135/88 112 147 48 143 4 1 6 43 27 1 5 1 0 6 1 17 0 2
27 45 F NH 1 1 2 2 2 88 23 132/90 111 138 46 141 4 1 6 45 29 1 3 2 0 5 1 18 0 2
28 51 F H 1 1 2 2 2 90 24 130/92 99 139 45 153 5 1 5 51 23 2 5 2 0 7 2 0 16 2
29 57 F H 1 1 2 2 2 95 27 136/92 96 146 49 151 4 1 5 57 24 2 5 3 0 8 2 0 14 2
30 53 F H 1 1 2 2 2 97 28 130/90 97 141 48 152 4 1 6 53 23 2 5 2 0 7 2 0 17 2
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M 15 NH 2 2 2 2 2 80 22 110/70 68 120 49 141 2.8 0.8 0.7 18 16 1 2 0 0 2 1 18 0 1 2 2
2
M 21 H 2 1 1 2 2 82 21 114/80 79 134 44 132 2.6 1.5 1.7 24 20 2 2 1 0 3 1 20 0 1 2 2
3
M 23 H 2 1 1 2 2 84 23 122/76 82 127 56 145 3.2 1.7 2.3 25 21 2 2 1 0 3 1 19 0 1 1 1
4
M 26 H 2 1 1 2 2 79 18 120/70 90 139 50 139 3.6 0.9 2.9 26 21 1 3 1 0 4 2 0 13 1 1 1
5
M 28 H 2 1 1 2 2 86 20 120/76 94 128 44 136 2.9 1.1 1.9 30 28 1 2 0 0 2 1 21 0 1 2 2
6
M 29 H 1 2 1 2 2 81 19 110/82 88 131 48 138 2.8 1.2 3.1 29 26 1 3 1 0 4 1 20 0 1 1 2
7
M 31 H 1 2 1 2 2 84 22 110/80 76 111 51 129 3.9 1.4 2.3 31 27 1 2 2 0 4 1 18 0 1 1 2
8
M 35 H 1 2 1 2 2 80 20 120/70 79 119 49 152 3.5 0.8 5.2 35 25 1 2 2 1 5 1 17 0 1 1 2
9
M 36 H 1 1 1 2 2 85 22 126/70 90 122 45 126 3.8 1.1 1.6 36 24 1 3 2 0 5 2 0 14 1 1 1
10
M 38 H 1 2 1 2 2 91 29 120/80 80 127 50 156 2.6 1.2 1.9 38 25 1 3 1 2 6 2 0 13 1 2 2
11
M 38 H 1 1 1 2 2 87 22 110/82 94 120 49 158 2.9 1.5 1.7 38 26 1 4 1 0 5 1 21 0 1 1 2
12
M 39 H 1 2 1 2 2 86 22 120/90 98 124 40 140 4.1 0.9 5.8 39 23 1 3 1 0 4 1 18 0 2 2 2
13
M 35 H 1 2 1 2 2 91 26 110/70 88 112 45 147 3.4 0.9 2.8 35 26 1 4 2 0 6 1 18 0 2 2 2
14
M 34 H 1 2 1 2 1 95 24 110/70 90 111 52 122 3.5 1.2 3.6 34 26 1 4 1 0 5 2 0 12 2 2 2
15
M 46 H 1 2 1 1 2 93 31 114/78 78 130 47 145 2.6 1.1 3.5 46 28 1 5 1 0 6 2 0 15 2 2 2
Alcohol use
Bipolar Disorder Without metabolic syndrome
S
l
.
N
O
S
e
x
A
g
e
R
e
l
i
g
i
o
n
M
a
r
i
t
a
l
 
s
t
a
t
u
s
E
d
u
c
a
t
i
o
n
O
c
c
u
p
a
t
i
o
n
L
o
c
a
l
i
t
y
D
i
e
t
W
C
B
M
I
B
P
F
B
S
P
P
B
S
H
D
L
T
G
T
3
C
u
r
r
e
n
t
 
e
p
i
s
o
d
e
No.of episodes
Y
M
R
S
H
A
M
D
T
4
T
S
H
A
g
e
A
g
e
 
a
t
 
o
n
s
e
t
 
I
n
d
e
x
 
e
p
i
s
o
d
e
Ma
n
i
a
D
e
p
r
e
s
s
i
o
n
M
i
x
e
d
T
o
t
a
l
U
s
e
A
b
u
s
e
D
e
p
e
n
d
e
n
c
e
Alcohol use
S
l
.
N
O
S
e
x
A
g
e
R
e
l
i
g
i
o
n
M
a
r
i
t
a
l
 
s
t
a
t
u
s
E
d
u
c
a
t
i
o
n
O
c
c
u
p
a
t
i
o
n
L
o
c
a
l
i
t
y
D
i
e
t
W
C
B
M
I
B
P
F
B
S
P
P
B
S
H
D
L
T
G
T
3
C
u
r
r
e
n
t
 
e
p
i
s
o
d
e
No.of episodes
Y
M
R
S
H
A
M
D
T
4
T
S
H
A
g
e
A
g
e
 
a
t
 
o
n
s
e
t
 
I
n
d
e
x
 
e
p
i
s
o
d
e
16
M 57 H 1 1 1 1 1 80 21 130/90 69 131 39 123 2.9 1.4 3.1 57 27 1 4 3 0 7 2 0 11 2 2 2
17
F 18 NH 2 1 1 2 2 68 19 130/80 82 134 51 125 2.8 1.3 1.9 29 25 1 3 0 0 3 1 20 0 2 2 2
18
F 20 H 2 1 1 2 2 72 18 120/90 80 125 55 129 3.1 1.5 1.6 28 20 3 3 0 2 5 1 21 0 2 2 2
19
F 21 H 2 1 1 2 2 71 20 110/74 90 136 53 137 3.5 1.1 2.4 29 26 1 2 0 0 2 1 19 0 2 2 2
20
F 27 H 1 2 1 2 2 69 19 124/80 77 115 52 136 3.9 1.6 2.7 28 26 1 2 0 0 2 1 18 0 2 2 2
21
F 29 H 1 2 1 2 2 73 22 122/78 87 117 54 142 4.2 0.8 5.8 29 25 1 3 0 0 3 1 17 0 2 2 2
22
F 32 H 1 2 2 2 2 77 21 110/74 88 121 54 156 3.2 1.5 1.6 32 28 1 2 0 0 2 1 24 0 2 2 2
23
F 32 H 1 2 1 2 2 78 19 130/88 94 122 56 128 2.7 1.3 3.1 32 26 1 2 0 1 3 1 26 0 2 2 2
24
F 33 H 1 1 2 2 2 76 22 120/80 96 119 51 130 4.2 0.9 5.4 33 25 1 3 1 0 4 1 28 0 2 2 2
25
F 35 H 1 1 2 1 2 87 29 110/70 80 122 52 125 2.8 1.4 3.2 35 28 1 3 0 0 3 1 19 0 2 2 2
26
F 39 H 1 2 2 1 2 79 21 126/88 80 130 50 140 3.1 0.8 5.7 39 27 1 3 2 0 5 2 0 14 2 2 2
27
F 40 H 1 1 2 2 2 86 30 120/80 86 130 56 130 3.3 1.2 1.9 40 27 1 3 1 0 4 1 23 0 2 2 2
28
F 40 NH 1 1 2 2 2 81 23 120/70 90 126 57 115 3.8 1.1 2.3 40 26 1 1 4 0 5 2 0 14 2 2 2
29
F 42 H 1 1 2 1 2 82 24 110/80 68 100 51 126 4.1 0.9 5.9 42 28 1 2 2 0 4 2 0 15 2 2 2
30
F 44 H 1 1 2 1 1 85 25 100/80 84 114 60 133 3.9 0.8 2.6 44 28 1 2 4 0 6 2 0 12 2 2 2
31
F 49 H 1 1 2 1 1 88 29 120/86 88 100 56 154 2.7 0.9 1.8 49 23 2 2 4 0 6 2 0 13 2 2 2
